Welcome to LookChem.com Sign In|Join Free

CAS

  • or

203066-91-5

Post Buying Request

203066-91-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

203066-91-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 203066-91-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,3,0,6 and 6 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 203066-91:
(8*2)+(7*0)+(6*3)+(5*0)+(4*6)+(3*6)+(2*9)+(1*1)=95
95 % 10 = 5
So 203066-91-5 is a valid CAS Registry Number.
InChI:InChI=1/C14H19FO2/c1-3-4-5-6-9-17-12-7-8-13(11(2)16)14(15)10-12/h7-8,10H,3-6,9H2,1-2H3

203066-91-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(2-fluoro-4-hexoxyphenyl)ethanone

1.2 Other means of identification

Product number -
Other names 1-acetyl-2-fluoro-4-hexyloxybenzene

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:203066-91-5 SDS

203066-91-5Downstream Products

203066-91-5Relevant articles and documents

Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors

Jong, Yeon Hwang,Arnold, Leggy A.,Zhu, Fangyi,Kosinski, Aaron,Mangano, Thomas J.,Setola, Vincent,Roth, Bryan L.,Guy, R. Kiplin

supporting information; experimental part, p. 3892 - 3901 (2010/02/17)

We have previously reported the discovery and preliminary structure activity relationships of a series of β-aminoketones that disrupt the binding of coactivators to TR. However, the most active compounds had moderate inhibitory potency and relatively high cytotoxicity, resulting in narrow therapeutic index. Additionally, preliminary evaluation of in vivo toxicology revealed a significant dose related cardiotoxicity. Here we describe the improvement of pharmacological properties of thyroid hormone receptor coactivator binding inhibitors. A comprehensive survey of the effects of substitutents in key areas of the molecule was carried out based on mechanistic insight from the earlier report. This study revealed that both electron withdrawing and hydrophobic substituents on the aromatic ring led to higher potency. On the other hand, moving from an alkyl to a sulfonyl alkyl side chain led to reduced cytotoxicity. Finally, utilization of amine moieties having low pKa's resulted in lowered ion channel activity without any loss of pharmacological activity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 203066-91-5